Clinical Trials Browser

Phase 3 × INDUSTRY × Smoldering Multiple Myeloma × Clear all

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT07393282 2026-03-16

LINKER-SMM2

Phase 3 Not yet recruiting

Smoldering Multiple Myeloma, Multiple Myeloma